Sun Pharmaceutical

Sun Pharmaceutical Industries has announced the resolution of its litigation with U.S.-based Incyte Corporation, marking a significant step toward clearing legal uncertainties that have hovered over the company’s operations. The settlement, involving terms that remain confidential, effectively ends a dispute centered on intellectual property rights and commercial interests. For Sun Pharma, the agreement removes a potential overhang on its growth plans in the critical U.S. market while reinforcing its commitment to collaborative business practices.

Sun Pharmaceutical Industries is set to invest USD 100 million in the current fiscal year to bolster the commercialization of innovative specialty drugs, signaling a focused push into patented therapies. Chairman and Managing Director Dilip Shanghvi outlined plans to prioritize the launch of two key products, Unloxcyt and Leqselvi, targeting metastatic cutaneous squamous cell carcinoma and severe alopecia areata, respectively.

India’s benchmark equity indices opened with robust momentum on Wednesday morning, defying global market hesitancy. The Sensex surged over 570 points to reach 81,760.05, while the Nifty rose by nearly 180 points to 24,863.55, reflecting investor confidence in domestic fundamentals. Leading the early gains were pharmaceutical heavyweights including Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Cipla, each posting notable advances. Bharat Electronics Ltd.

In a troubling turn for Indian pharmaceutical giants, Glenmark, Sun Pharma, and Zydus are facing product recalls in the United States due to regulatory non-compliance and manufacturing deficiencies. The U.S. Food and Drug Administration (USFDA) flagged multiple deviations from Current Good Manufacturing Practices (CGMP), leading to recalls of widely prescribed medications for cardiac conditions, neurological disorders, and mental health issues. These enforcement actions highlight rising regulatory vigilance in the U.S.

Sun Pharmaceutical Industries Ltd has secured a critical legal victory in the United States that effectively lifts restrictions on the launch of its drug LEQSELVI (deuruxolitinib), used in the treatment of autoimmune-related hair loss (alopecia areata). The U.S. Court of Appeals for the Federal Circuit vacated a prior injunction imposed by a lower court, freeing Sun Pharma to move forward with its commercialization plans.

Sun Pharmaceutical Industries, a prominent player in the Indian pharmaceutical sector, made a significant announcement on Monday with the launch of its new medication, Fexuprazan, marketed under the brand name Fexuclue. This novel treatment is specifically designed for Erosive Esophagitis, a severe condition that significantly impacts patients’ quality of life. Despite an unmet medical need, the company’s stock saw a slight dip, reflecting investor caution amid a fluctuating market environment.

The latest recommendation from ICICI Securities reflects confidence in Sun Pharma’s specialty growth strategy, underpinned by its acquisition of Checkpoint Therapeutics for a total potential outlay of USD 355 million. This acquisition secures access to Unloxcyt (cosibelimab)—an FDA-approved anti-PD-L1 monoclonal antibody for treating advanced cutaneous squamous cell carcinoma (cSCC), the second most common form of skin cancer. With annual deaths from advanced cSCC touching 15,000 in the U.S.